JP2017523790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523790A5 JP2017523790A5 JP2017506667A JP2017506667A JP2017523790A5 JP 2017523790 A5 JP2017523790 A5 JP 2017523790A5 JP 2017506667 A JP2017506667 A JP 2017506667A JP 2017506667 A JP2017506667 A JP 2017506667A JP 2017523790 A5 JP2017523790 A5 JP 2017523790A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pharmaceutical composition
- subject
- diabetes
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 8
- 239000002777 nucleoside Substances 0.000 claims 8
- 239000003937 drug carrier Substances 0.000 claims 6
- 208000030159 metabolic disease Diseases 0.000 claims 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 6
- 229910019142 PO4 Inorganic materials 0.000 claims 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 4
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 4
- 238000010276 construction Methods 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 208000010706 fatty liver disease Diseases 0.000 claims 4
- 239000010452 phosphate Substances 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 2
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000001280 Prediabetic State Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 150000004713 phosphodiesters Chemical class 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462034739P | 2014-08-07 | 2014-08-07 | |
| US62/034,739 | 2014-08-07 | ||
| US201462062749P | 2014-10-10 | 2014-10-10 | |
| US62/062,749 | 2014-10-10 | ||
| US201562143434P | 2015-04-06 | 2015-04-06 | |
| US62/143,434 | 2015-04-06 | ||
| PCT/US2015/043926 WO2016022753A1 (en) | 2014-08-07 | 2015-08-06 | Targeting micrornas for metabolic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017523790A JP2017523790A (ja) | 2017-08-24 |
| JP2017523790A5 true JP2017523790A5 (enExample) | 2018-09-06 |
Family
ID=53836884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506667A Ceased JP2017523790A (ja) | 2014-08-07 | 2015-08-06 | 代謝障害のためのマイクロｒｎａの標的化 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9487783B2 (enExample) |
| EP (1) | EP3177721A1 (enExample) |
| JP (1) | JP2017523790A (enExample) |
| KR (1) | KR20170033439A (enExample) |
| CN (1) | CN106559995A (enExample) |
| AU (1) | AU2015301057A1 (enExample) |
| BR (1) | BR112017001931A2 (enExample) |
| CA (1) | CA2953883A1 (enExample) |
| CL (1) | CL2017000312A1 (enExample) |
| CO (1) | CO2017000950A2 (enExample) |
| IL (1) | IL249819A0 (enExample) |
| MA (1) | MA40463A (enExample) |
| MX (1) | MX2017001493A (enExample) |
| RU (1) | RU2017105342A (enExample) |
| SG (1) | SG11201610877PA (enExample) |
| TW (1) | TW201613949A (enExample) |
| WO (1) | WO2016022753A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40463A (fr) | 2014-08-07 | 2017-06-14 | Regulus Therapeutics Inc | Ciblage de micro-arn pour traiter des troubles métaboliques |
| CN109475568B (zh) | 2016-05-06 | 2026-07-17 | Ionis制药公司 | Glp-1受体配体部分缀合的寡核苷酸及其用途 |
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| KR101869308B1 (ko) * | 2017-02-28 | 2018-06-20 | 대구가톨릭대학교산학협력단 | Srebp-1 디코이 올리고디옥시뉴클레오티드 및 이를 유효성분으로 함유하는 지방간 질환의 예방 또는 치료용 약학 조성물 |
| WO2019143767A1 (en) * | 2018-01-17 | 2019-07-25 | University Of Connecticut | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease |
| US11690804B2 (en) * | 2018-07-02 | 2023-07-04 | Aptamir Therapeutics, Inc. | Targeted delivery of therapeutic agents to human adipocytes |
| TW202019441A (zh) * | 2018-07-20 | 2020-06-01 | 美商雷格勒斯治療公司 | 用於經口遞送寡核苷酸之方法 |
| US10844383B1 (en) | 2019-09-18 | 2020-11-24 | Dasman Diabetes Institute | Microrna dyslipidemia inhibitor |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW520293B (en) | 1995-11-22 | 2003-02-11 | Univ Johns Hopkins Med | Delivery system to enhance cellular uptake of biomolecules |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
| AU2005325262B2 (en) | 2004-04-27 | 2011-08-11 | Alnylam Pharmaceuticals, Inc. | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety |
| EP2471924A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, INC. | Methods and compositions involving microRNA |
| EP2990410A1 (en) | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| ES2534300T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| AU2006279906B2 (en) | 2005-08-10 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| WO2007027894A2 (en) | 2005-08-29 | 2007-03-08 | Isis Pharmaceuticals, Inc. | Antisense compounds having enhanced anti-microrna activity |
| DE602007009487D1 (de) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-modifizierte bicyclische nukleinsäureanaloga |
| EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
| CA3042781C (en) | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| CA3144493A1 (en) | 2006-10-03 | 2008-04-10 | Arbutus Biopharma Corporation | Lipid containing formulations |
| CN101121934B (zh) | 2007-04-11 | 2011-12-07 | 哈尔滨医科大学 | 多靶点miRNA反义核苷酸的制备方法 |
| DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
| WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| DK2205737T3 (da) | 2007-10-04 | 2013-05-21 | Santaris Pharma As | Mikromirer |
| EP2229186A2 (en) | 2007-12-04 | 2010-09-22 | Alnylam Pharmaceuticals Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| EP2268811A1 (en) | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| CA2763016C (en) | 2009-05-20 | 2018-04-17 | Eth Zurich | Targeting micrornas for metabolic disorders |
| MA33488B1 (fr) | 2009-06-08 | 2012-08-01 | Miragen Therapeutics | Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn |
| PH12012501596A1 (en) | 2010-02-24 | 2017-02-03 | Arrowhead Res Corporation | Compositions for targeted delivery of sirna |
| WO2011117353A1 (en) * | 2010-03-24 | 2011-09-29 | Mirrx Therapeutics A/S | Bivalent antisense oligonucleotides |
| RU2013117288A (ru) | 2010-12-17 | 2015-01-27 | Эрроухэд Рисерч Корпорейшн | СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА |
| US8877722B2 (en) | 2011-03-25 | 2014-11-04 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting gene expression and uses thereof |
| US10023861B2 (en) | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| HK1200484A1 (zh) | 2011-09-14 | 2015-08-07 | Translate Bio Ma, Inc. | 多聚寡核苷酸化合物 |
| EP3254700B1 (en) | 2012-03-04 | 2019-10-23 | Bonac Corporation | Micro-rna inhibitor |
| EP2864482A4 (en) | 2012-06-21 | 2016-02-10 | Miragen Therapeutics Inc | OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN |
| US9163235B2 (en) | 2012-06-21 | 2015-10-20 | MiRagen Therapeutics, Inc. | Inhibitors of the miR-15 family of micro-RNAs |
| US20150247141A1 (en) | 2012-09-14 | 2015-09-03 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
| CN104955950B (zh) | 2012-09-26 | 2019-04-26 | 米尔克斯治疗学公司 | 具有改善的脱靶特征谱的寡核苷酸 |
| CA2889044A1 (en) * | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| CA2893801A1 (en) | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| EP2992096B1 (en) | 2013-05-01 | 2021-03-03 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
| US10358643B2 (en) | 2014-01-30 | 2019-07-23 | Hoffmann-La Roche, Inc. | Poly oligomer compound with biocleavable conjugates |
| MA40463A (fr) | 2014-08-07 | 2017-06-14 | Regulus Therapeutics Inc | Ciblage de micro-arn pour traiter des troubles métaboliques |
-
2015
- 2015-08-06 MA MA040463A patent/MA40463A/fr unknown
- 2015-08-06 WO PCT/US2015/043926 patent/WO2016022753A1/en not_active Ceased
- 2015-08-06 US US14/819,648 patent/US9487783B2/en not_active Expired - Fee Related
- 2015-08-06 BR BR112017001931A patent/BR112017001931A2/pt not_active Application Discontinuation
- 2015-08-06 JP JP2017506667A patent/JP2017523790A/ja not_active Ceased
- 2015-08-06 CN CN201580039229.9A patent/CN106559995A/zh active Pending
- 2015-08-06 SG SG11201610877PA patent/SG11201610877PA/en unknown
- 2015-08-06 AU AU2015301057A patent/AU2015301057A1/en not_active Abandoned
- 2015-08-06 MX MX2017001493A patent/MX2017001493A/es unknown
- 2015-08-06 CA CA2953883A patent/CA2953883A1/en not_active Abandoned
- 2015-08-06 RU RU2017105342A patent/RU2017105342A/ru not_active Application Discontinuation
- 2015-08-06 EP EP15750573.6A patent/EP3177721A1/en not_active Withdrawn
- 2015-08-06 TW TW104125684A patent/TW201613949A/zh unknown
- 2015-08-06 KR KR1020177005873A patent/KR20170033439A/ko not_active Withdrawn
-
2016
- 2016-09-22 US US15/272,619 patent/US9862950B2/en not_active Expired - Fee Related
- 2016-12-28 IL IL249819A patent/IL249819A0/en unknown
-
2017
- 2017-02-01 CO CONC2017/0000950A patent/CO2017000950A2/es unknown
- 2017-02-07 CL CL2017000312A patent/CL2017000312A1/es unknown
- 2017-10-05 US US15/725,843 patent/US10138484B2/en not_active Expired - Fee Related
-
2018
- 2018-09-25 US US16/140,881 patent/US20190153444A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016041733A5 (enExample) | ||
| JP2017505116A5 (enExample) | ||
| JP2018510621A5 (enExample) | ||
| JP2018507914A5 (enExample) | ||
| Ibañez et al. | M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A | |
| JP2017515854A5 (enExample) | ||
| JP2013516489A5 (enExample) | ||
| JP2018523668A5 (enExample) | ||
| JP2018535967A5 (enExample) | ||
| JP2022511394A5 (enExample) | ||
| JP2013537423A5 (enExample) | ||
| JP2019507781A5 (enExample) | ||
| JP2011157378A5 (enExample) | ||
| JP2013518815A5 (enExample) | ||
| JP2015534580A5 (enExample) | ||
| JP2011219478A5 (enExample) | ||
| JP2014503593A5 (enExample) | ||
| JP2012521217A5 (enExample) | ||
| JP2017515901A5 (enExample) | ||
| JP2016502504A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2020503017A5 (enExample) | ||
| JP2018505882A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| JP2015530399A5 (enExample) |